Abbott Laboratories (NYSE: ABT) operates as a highly diversified global healthcare conglomerate, structured around four primary operating segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceutical Products (EPD). The fundamental posture of the company as of early 2026 reflects a structural transition. Having fully cycled through the unprecedented revenue surges generated by COVID-19 rapid testing during the pandemic, the enterprise has successfully repositioned its growth engine toward its Medical Devices segment, particularly within continuous glucose monitoring (CGM) and electrophysiology. The analysis of Abbott’s fundamental standing requires a comprehensive review of its five-year financial performance, capital structure evolution, and the strength of its underlying economic moat.